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Background: Hereditary haemochromatosis (HH) is the most common and probably the most 
treatable genetic disorder in Europe, but many patients are misdiagnosed or diagnosed too late.  HH 
causes iron overload and is predominantly due to the HFE p.C282Y genetic variant. HH is easily 
prevented and treated with phlebotomy. We aimed to test HFE p.C282Y homozygote associations 
with prevalent and incident morbidity in the large UK Biobank sample of European descent. We also 
examined how iron supplement use may affect associations between p.C282Y homozygosity and 
morbidity. 
 
Methods: We studied 451,243 participants of European descent (aged 40 to 70 years) from the UK 
Biobank. Data were available on prevalent and incident adverse health outcomes from baseline 
questionnaires and from up to 9.4 years hospital inpatient follow-up (mean 7 years). Participants 
also reported baseline dietary supplement use. We tested associations between p.C282Y 
homozygosity, prevalent and incident outcomes, and iron supplement use, using logistic regression 
and Cox proportional hazard regression, adjusted for age, sex, genotyping array type and genetic 
principal components. 
 
Results: 2,890 participants were p.C282Y homozygotes (0.6%, or 1/156), of whom 7.3% (210/2890) 
had haemochromatosis diagnosed at baseline, increasing to 15.1% (437/2890) by the end of follow-
up. P.C282Y homozygotes had substantial excess prevalent and incident morbidity including 
haemochromatosis, liver disease, arthritis and diabetes compared to those with no mutations  
(combined measure of excess incident morbidity; men, HR: 3.37, 95% CI: 2.87-3.97; women, HR: 
2.99,95% CI: 2.51-3.55). A sub-analysis of 200,975 older participants (aged 60-70 years) showed that 
both male and female p.C282Y homozygotes also had an increased likelihood of Fried frailty and 
chronic pain.  
 
In p.C282Y homozygotes undiagnosed with haemochromatosis, the intake of iron supplements or 
multivitamins increased the likelihood of frailty (OR: 2.15, 95% CI: 1.22-3.77) and incident 
osteoarthritis (HR: 1.86, 95% CI: 1.02-3.41). 
 
Conclusions: In a large community volunteer sample, HFE p.C282Y homozygosity was associated 
with substantial excess morbidity, frailty and chronic pain in both men and women. In p.C282Y 
homozygotes undiagnosed with haemochromatosis, taking iron supplements or multivitamins was 
an additional risk factor for developing morbidity, including frailty and osteoarthritis. Since the 
p.C282Y associated iron overload can be prevented and treated, these findings suggest there is a 
need for expanded case finding and screening for hereditary haemochromatosis. It also suggests 
that warnings and controls on iron containing supplements may be needed.  
 
